On January 26th, 2023, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) for EVUSHELD to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, EVUSHELD is not currently authorized for use in the U.S. until further notice by the Agency.
The U.S. Government recommends that facilities and providers with unexpired EVUSHELD retain all product in the event that SARS-CoV-2 variants which are neutralized by EVUSHELD become more prevalent in the U.S. in the future.
Please refer to the HHS website for expiry extension information.
You’re leaving the EVUSHELD website